ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > IMMUSAFE.COM

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Apr 21, 2021 10:05am

107 Views

Post# 33036368

RE:RE:RE:IMMUSAFE.COM

at about $160 per test, given the current price on the website and the planned a 50-50 split between PMN and BCNI

I wonder if they are keeping this quiet due to potential ongoing non-exclusive licensing negotiations.

If the market for this type of analysis is as big as I hope, and especially if insurance covers these tests in some or all cases, they would need more than one lab processing all those samples.

Who knows, but it is looking good to me.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec